SilverArc reports 5.02% stake in NextCure
SilverArc Capital Management, LLC and its sole member Devesh Gandhi report beneficial ownership of 176,057 shares of NextCure, Inc. Class A common stock, representing 5.02% of the class as of 12/31/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SilverArc Capital Management, LLC and its sole member Devesh Gandhi report beneficial ownership of 176,057 shares of NextCure, Inc. Class A common stock, representing 5.02% of the class as of 12/31/2025. All voting and dispositive power over these shares is shared, with no sole authority reported.
SilverArc is an SEC-registered investment adviser, and the shares are held for various advisory clients, who have the right to receive dividends and sale proceeds. Within this total, SilverArc Capital Alpha Fund I, L.P. is attributed 6,162 shares (about 0.18%), and SilverArc Capital Alpha Fund II, L.P. is attributed 169,895 shares (about 4.85%). The filing states the position is held in the ordinary course of business and not for the purpose of influencing control of NextCure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in NextCure (NXTC) does SilverArc Capital report?
Who are the reporting persons in this NextCure (NXTC) Schedule 13G?
How is SilverArc’s 5.02% NextCure (NXTC) ownership structured?
Does SilverArc intend to influence control of NextCure (NXTC)?
On what date is SilverArc’s 5.02% NextCure (NXTC) position reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.